Literature DB >> 6843115

The dissociation of testosterone- and 5 alpha-dihydrotestosterone-receptor complexes formed within cultured human genital skin fibroblasts.

M Kaufman, L Pinsky.   

Abstract

We have studied the rate and character with which testosterone (T) and 5 alpha-dihydrotestosterone (DHT) dissociate from the androgen receptor both within intact cultured genital skin fibroblasts of a subject with 5 alpha-reductase deficiency and after the androgen-receptor complexes have been extracted from the cells. Within the cells, the kinetics of the dissociative process for each hormone was first-order, but T dissociated four times faster than DHT. An Arrhenius plot of the variation of the dissociation rate constants with temperature for T was linear and yielded an activation energy of 28 kcal/mol. This value is identical with the one previously determined for activated DHT-receptor complexes. T-receptor complexes extracted from the cells dissociated with complex kinetics: at 37 degrees C the rate constants of the "fast" and "slow" components were 40 and 14 X 10(-3) min-1, respectively. In contrast, DHT-receptor complexes extracted from the cells dissociated with first-order kinetics and at a rate identical to that observed within cells, except after exposure to pyridoxal 5'-phosphate (5 mM) or concentration by Amicon (B-15) filtration, when their dissociation kinetics became complex. We interpret these data to mean that, within the cells, both T- and DHT-receptor complexes exist predominantly in the activated state whereas, when extracted from the cells, DHT-receptor complexes remain activated, unless perturbed, while T-receptor complexes become unstable spontaneously, probably by reverting to a preactivated state.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6843115     DOI: 10.1016/0022-4731(83)90077-8

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  7 in total

Review 1.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

2.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

3.  Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes.

Authors:  M S Mahendroo; K M Cala; D L Hess; D W Russell
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

4.  Chronic administration of androgens with actions at estrogen receptor beta have anti-anxiety and cognitive-enhancing effects in male rats.

Authors:  Danielle M Osborne; Kassandra Edinger; Cheryl A Frye
Journal:  Age (Dordr)       Date:  2009-03-05

5.  Chronic administration of androgens with actions at estrogen receptor beta have anti-anxiety and cognitive-enhancing effects in male rats.

Authors:  Danielle M Osborne; Kassandra Edinger; Cheryl A Frye
Journal:  Age (Dordr)       Date:  2009-08-15

6.  Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice.

Authors:  Sara H Windahl; Niklas Andersson; Anna E Börjesson; Charlotte Swanson; Johan Svensson; Sofia Movérare-Skrtic; Klara Sjögren; Ruijin Shao; Marie K Lagerquist; Claes Ohlsson
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

7.  Role of androgens in dhea-induced rack1 expression and cytokine modulation in monocytes.

Authors:  Emanuela Corsini; Valentina Galbiati; Angela Papale; Elena Kummer; Antonella Pinto; Melania M Serafini; Antonio Guaita; Roberto Spezzano; Donatella Caruso; Marina Marinovich; Marco Racchi
Journal:  Immun Ageing       Date:  2016-05-29       Impact factor: 6.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.